Literature DB >> 25935456

Ankylosis in ankylosing spondylitis: current concepts.

Nigil Haroon1.   

Abstract

Ankylosing spondylitis (AS) is the most common form of spondyloarthritis and is characterized by both inflammation and new bone formation. Despite many years of arduous efforts, we still do not clearly understand the pathogenesis of AS. The mechanisms behind new bone formation have been especially challenging to decipher due to the difficulty in obtaining tissue from spinal joints. The link between inflammation and bone formation looks obvious, but how inflammation drives spinal fusion is not evident. There are now two genes linked to prostaglandins (PG) that could be involved in AS pathogenesis. The first one is PTGER4 that codes for the EP4 receptor for PGE2 and the other one is PTGS1 that codes for prostaglandin-endoperoxide syntase 1 or cyclogenase 1. The bone morphogenic protein and Wnt signaling pathways could be important in signaling increased bone formation in AS. The disease-modifying potential of anti-inflammatories and tumor necrosis factor alpha inhibitors is discussed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25935456     DOI: 10.1007/s10067-015-2956-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  56 in total

1.  Anterior neural development requires Del1, a matrix-associated protein that attenuates canonical Wnt signaling via the Ror2 pathway.

Authors:  Akira Takai; Hidehiko Inomata; Akiko Arakawa; Rieko Yakura; Mami Matsuo-Takasaki; Yoshiki Sasai
Journal:  Development       Date:  2010-10       Impact factor: 6.868

2.  The natural disease course of ankylosing spondylitis.

Authors:  S Carette; D Graham; H Little; J Rubenstein; P Rosen
Journal:  Arthritis Rheum       Date:  1983-02

3.  Assessment of work instability in spondyloarthritis: a cross-sectional study using the ankylosing spondylitis work instability scale.

Authors:  Isabelle Fabreguet; Eugénie Koumakis; Vincent Burki; Anne Durnez; Muriel Elhai; Magali Meyer; Simon Paternotte; Judith Payet; Fanny Roure; Bruno Fautrel; Maxime Dougados; Laure Gossec
Journal:  Rheumatology (Oxford)       Date:  2011-11-15       Impact factor: 7.580

4.  MicroRNA-124 involves in ankylosing spondylitis by targeting ANTXR2.

Authors:  Yu Xia; Kun Chen; Ming-Hua Zhang; Lai-Cheng Wang; Chun-Yan Ma; Yan-Liang Lin; Yue-Ran Zhao
Journal:  Mod Rheumatol       Date:  2015-07-20       Impact factor: 3.023

5.  High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion.

Authors:  Scott S Reuben; David Ablett; Rachel Kaye
Journal:  Can J Anaesth       Date:  2005-05       Impact factor: 5.063

6.  The impact of tumor necrosis factor α inhibitors on radiographic progression in ankylosing spondylitis.

Authors:  Nigil Haroon; Robert D Inman; Thomas J Learch; Michael H Weisman; MinJae Lee; Mohammad H Rahbar; Michael M Ward; John D Reveille; Lianne S Gensler
Journal:  Arthritis Rheum       Date:  2013-10

7.  Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells.

Authors:  Peggy Jacques; Stijn Lambrecht; Eveline Verheugen; Elin Pauwels; George Kollias; Maria Armaka; Marleen Verhoye; Annemie Van der Linden; Rik Achten; Rik J Lories; Dirk Elewaut
Journal:  Ann Rheum Dis       Date:  2013-08-06       Impact factor: 19.103

8.  Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.

Authors:  Xenofon Baraliakos; Hildrun Haibel; Joachim Listing; Joachim Sieper; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-03-16       Impact factor: 19.103

9.  Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis.

Authors:  Dimitrios Daoussis; Stamatis-Nick C Liossis; Elena E Solomou; Anastasia Tsanaktsi; Konstadina Bounia; Maria Karampetsou; Georgios Yiannopoulos; Andrew P Andonopoulos
Journal:  Arthritis Rheum       Date:  2010-01

10.  Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci.

Authors:  John D Reveille; Anne-Marie Sims; Patrick Danoy; David M Evans; Paul Leo; Jennifer J Pointon; Rui Jin; Xiaodong Zhou; Linda A Bradbury; Louise H Appleton; John C Davis; Laura Diekman; Tracey Doan; Alison Dowling; Ran Duan; Emma L Duncan; Claire Farrar; Johanna Hadler; David Harvey; Tugce Karaderi; Rebecca Mogg; Emma Pomeroy; Karena Pryce; Jacqueline Taylor; Laurie Savage; Panos Deloukas; Vasudev Kumanduri; Leena Peltonen; Sue M Ring; Pamela Whittaker; Evgeny Glazov; Gethin P Thomas; Walter P Maksymowych; Robert D Inman; Michael M Ward; Millicent A Stone; Michael H Weisman; B Paul Wordsworth; Matthew A Brown
Journal:  Nat Genet       Date:  2010-01-10       Impact factor: 38.330

View more
  4 in total

1.  Baseline increased 18F-fluoride uptake lesions at vertebral corners on positron emission tomography predict new syndesmophyte development in ankylosing spondylitis: a 2-year longitudinal study.

Authors:  Eun-Kyoung Park; Kyoungjune Pak; Ji-Heh Park; Keunyoung Kim; Seong-Jang Kim; In-Joo Kim; Geun-Tae Kim; Seung-Geun Lee
Journal:  Rheumatol Int       Date:  2017-02-02       Impact factor: 2.631

2.  Comparison of MRI-defined back muscles volume between patients with ankylosing spondylitis and control patients with chronic back pain: age and spinopelvic alignment matched study.

Authors:  Doo Hee Bok; Jihye Kim; Tae-Hwan Kim
Journal:  Eur Spine J       Date:  2016-11-24       Impact factor: 3.134

3.  Insight on Bone Morphogenetic Protein 7 in Ankylosing Spondylitis and its association with disease activity and radiographic damage.

Authors:  Adel Mahmoud; Dalia Fayez; Mervat Mammdouh Abou Gabal; Sherin Mohamed Hosny Hamza; Takwa Badr
Journal:  Electron Physician       Date:  2016-07-25

4.  Protective effect of anthrax toxin receptor 2 polymorphism rs4333130 against the risk of ankylosing spondylitis.

Authors:  Haitao Xu; Yiming Qu
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.